Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Multicenter, Open-label, Study of FID-007 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma

NCT06332092 is registered in ClinicalTrials.gov with Fulgent Pharma LLC. as lead sponsor.

NCT NCT06332092
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06332092 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Multicenter, Open-label, Study of FID-007 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma
Lead sponsor
Fulgent Pharma LLC.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
April 10, 2024
Completion date
December 31, 2026
Enrollment
46 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck squamous cell carcinoma